Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless – Motley Fool
The Biological SCENE |
Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless
Motley Fool What's all the fuss about? The big-ticket item is that this journal article reported that most humans probably have pre-existing immune defenses against the "cutting element" in CRISPR known as Cas9. If true, the CRISPR-Cas9 gene-editing system may be … CRISPR is coming to the clinic this year | January 8, 2018 Issue – Vol … Key CRISPR gene editing methods might not work for most humans 3 Soaring Gene-Editing Biotech Stocks: Which Is the Best Buy? |
